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Hierarchical Interactions Control CD4 Gene
Expression during Thymocyte Development
ment, and the changes in CD4 and CD8 expression are
not yet fully understood (Ellmeier and Kioussis, 2002;
Lucas and Germain, 1996; Singer, 2002; Siu, 2002).
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Integrated Program of Cellular, Molecular As CD4 and CD8 transcription is closely coupled to
thymocyte development, understanding how the geneand Biophysical Studies
630 West 168th Street is regulated should provide insight into the molecular
mechanisms and developmental cues that drive thymo-Columbia University College of Physicians
and Surgeons poiesis. Although a variety of technologies have been
applied to the study of how these genes are controlled,New York, New York 10032
the transgenic reporter assay has provided a prolific
amount of data to determine the roles of control ele-
ments in vivo. In addition, the transgenic approach rep-Summary
resents a reductionist strategy that can determine true
cause-and-effect relationships of individual control ele-CD4 gene regulation provides an ideal model for un-
ments. This critical aspect of transcriptional control can-derstanding the molecular events that drive T cell de-
not be easily addressed with in situ element mutagene-velopment. In this paper we use a transgenic approach
sis studies.to identify a CD4 LCR containing a stage-specific thy-
To date, four cis-acting control elements in the CD4mocyte enhancer (TE) and a region that protects
locus have been defined: a promoter, a silencer, a proxi-against position effect variegation. Surprisingly, the TE
mal enhancer (PE), and a distal enhancer (DE, DH1;acts indirectly through the previously defined proximal
Figure 1). Transgenic assays conducted by our groupenhancer and is strongly induced upon commitment to
and others had determined that these elements werethe T cell lineage. We also describe a complex series
not sufficient to induce physiologically significant levelsof hierarchical control element interactions that or-
of CD4 expression in DP thymocytes. DE-driven trans-chestrate CD4 expression throughout thymopoiesis.
genes were not expressed at all, whereas PE-drivenThese data provide a framework for understanding
transgenes were induced at the cessation of TCR selec-how CD4 gene expression is regulated in response to
tion. Addition of the CD4 silencer to these PE-drivenlineage commitment decisions.
constructs further limited expression to mature CD4 T
cells only (our unpublished data; Adlam et al., 1997;Introduction
Boyer et al., 1997; Duncan et al., 1996; Salmon et al.,
1996; Uematsu et al., 1997). These data indicated thatThe molecular processes and developmental cues that
there was an additional unidentified control element re-drive thymopoiesis have not been completely defined.
sponsible for driving CD4 expression in DP thymo-Hematopoietic stem cells (HSCs) that reside in the bone
poiesis (Adlam et al., 1997; Siu, 2002).marrow generate the common lymphoid progenitor (CLP),
In this paper we identify a CD4 locus enhancer, termedwhich migrates to the thymus to give rise to the double-
the thymocyte enhancer (TE), that is critical for inducingnegative (DN) thymocyte population. The DN population
CD4 gene expression in immature thymocytes. We alsohas been divided into four serial developmental stages
identify a region adjacent to the TE that conveys robust(DN1–DN4). The DN1 population is oligopotent, with T
and position effect variegation (PEV) resistant expres-cell lineage commitment occurring at the DN1-to-DN2
sion of the linked transgenic reporter. Therefore, to-transition. TCR  chain gene rearrangement induces the
gether with the TE, this region constitutes a novel CD4differentiation of the DN2 thymocyte to the DN3 stage.
LCR that acts to ensure robust and timely expressionThese cells then undergo  chain selection, eventually
of CD4. In addition, we have mapped the temporal func-yielding the DN4 thymocyte. The DN4 cell subsequently
tion of the CD4 control elements. We find that CD4upregulates both CD4 and CD8 expression, defining the
expression throughout thymopoiesis requires a hierar-double-positive (DP) thymocyte (Ceredig and Rolink,
chical and coordinated series of developmentally re-2002; Zuniga-Pflucker et al., 1995). Upon successful
sponsive interactions between each of these elements.TCR  chain gene rearrangement and surface expres-
The CD4 gene is thus an ideal model to study the molec-sion of TCR, the DP thymocyte undergoes repertoire
ular mechanisms involved in driving lineage commit-selection and another lineage commitment decision to-
ment and T cell development.ward either a CD4 SP T cell or CD8 SP T cell fate (Guidos,
1996). It is believed that during this process the DP
thymocyte progresses through different transitional Results
stages characterized by modulations of CD4 and CD8
expression. However, the order of these transitions and Double-Positive Thymocytes Utilize a Distinct CD4
Locus Enhancerthe mechanisms that link selection, lineage commit-
Previous transgenic data from our group and others
had indicated that the PE was incapable of driving CD4*Correspondence: matthew.adlam@mssm.edu
expression in DP thymocytes. Indeed, this enhancer was1 Present Address: Amgen Inc., 29-M-B, One Amgen Center Drive,
Thousand Oaks, California 91320. induced to function at the cessation of positive selection
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Figure 1. Schematic Maps of the CD4 Locus and Transgene Reporter Constructs
Horizontal striped boxes, proximal enhancer (PE); stippled boxes, CD4 promoter (Pr); gray boxes, silencer (Sil); white boxes, CD4 LCR; hatched
boxes, thymocyte enhancer (TE); DNase hypersensitive site, arrow (DH).
(A) Schematic map of the CD4 locus. Genes are indicated above the map, and the exons of CD4 are highlighted as black filled boxes above
the line; all other gene exons are hollow boxes above the line. DNase I hypersensitive sites (DHs) are indicated with arrows and numbers. All
DHs are present in all T cell lines tested, with the exception of DH16, which is absent in CD4/CD8 lines.
(B) Schematic of transgene constructs. All constructs contain the basic reporter cassette containing the promoter and untranslated first exon
of CD4 (stippled box, Pr) fused to the reporter cDNA, HLA-B7, and -globin UTR. Restriction fragments containing DHs (arrows) or previously
defined control elements (boxes) of the CD4 locus were added to the expression reporter cassette as indicated in the Experimental Procedures.
The total number of expressing founders and total number of transgenic founder lines are listed next to the construct name on the left (total
expressing lines/total founder lines). Expression was assessed by FACS with PE-conjugated anti-HLA-B7; transgenesis was assessed by
Southern blot.
as surface expression of CD69 and HSA decreases (Ad- expressed the marker only in a subset of mature SP T
cells and not in DP thymocytes, similar to the pTG andlam et al., 1997; Salmon et al., 1996; Uematsu et al.,
1997). As shown in Figure 2, transgene marker expres- pA5UA transgenic thymocytes. These data suggested
that DH17 is required for CD4 expression in DP thymo-sion was not detected in DP thymocytes of mice trans-
genic with the pA5UA and pTG constructs, both of which cytes. To test this directly, we generated the pI construct
by adding DH11-17 to the pTG construct (Figure 1). Ascontain the CD4 promoter and PE. In contrast, the larger
B and cosC constructs carrying DH11-17 as well as shown in Figure 2, all DP and CD4 SP thymocytes from
pI transgenic mice express the marker, consistent withthe CD4 promoter and PE expressed marker in DP thy-
mocytes. These data indicated that there is a novel en- the hypothesis that DH17 contains the enhancer respon-
sible for driving CD4 expression in DP thymocytes.hancer located in DH11-17 that conveys expression in
DP thymocytes (Adlam et al., 1997).
To map the enhancer responsible for driving CD4 gene The Thymocyte Enhancer Is Located in the First
Intron of ISOTexpression in DP thymocytes, we added fragments of
DH11-17 back into the pTG construct, generated addi- Sequence analysis revealed that the 3 kb fragment con-
taining DH17 maps to the 5 region of the housekeepingtional transgenic mice, and analyzed the specificity of
marker expression for each construct. The pH construct gene ISOT (Ansari-Lari et al., 1996). To confirm that DH17
indeed contains a traditional transcriptional enhancer,is pTG with the addition of a 6 kb fragment containing
DH11-16 (Figure 1). If the thymocyte enhancer is present we analyzed the enhancer activity of this fragment using
a transient transfection assay (Figure 3). Fragments ofin DH11-16, we would predict that mice transgenic with
this construct would express the marker in DP thymo- DH17 were subcloned into a luciferase reporter con-
struct under the transcriptional control of the CD4 pro-cytes. As shown in Figure 2, pH transgenic thymocytes
CD4 Gene Regulation throughout Thymopoiesis
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Figure 2. Transgene Expression in Immature Double-Positive Thymocyte Is Dependent on DH17
FACS analysis of transgene marker expression in DP and CD4 SP thymocyte populations. Thymocyte subpopulations were electronically
gated as previously described and marker expression assessed (Duncan et al., 1996). Gray-filled polygon, marker expression on transgenic
thymocytes; black line, nontransgenic littermate.
moter (Sarafova and Siu, 1999). These constructs were fragment caused a small decrease in luciferase activity,
whereas addition of the B fragment caused an approxi-then transfected into the DP thymoma AKR1G1, and the
cells were assayed for luciferase activity. As shown in mate 30-fold increase in luciferase activity. Moreover,
this B fragment strongly activated transcription in a posi-Figure 3B, addition of the 3 kb A/B fragment led to a
15-fold increase in luciferase activity. Addition of the A tion- and orientation-independent manner. These data
Figure 3. The Thymocyte Enhancer Is Located in the First Intron of ISOT
(A) Schematic map of the 3 kb fragment that contains DH17. Black boxes above the horizontal line indicate the exon of ISOT; the arrow
indicates the direction of transcription. X, XhoI site; B, BamHI site; RV, EcoRV site (vertical black line). An enlarged map of the fragment
containing DH17 is shown below, with the fragments that were inserted into CD4 promoter driven pGL3 transfection reporter below.
(B) The ISOT intronic B fragment contains a position- and orientation-independent enhancer. As shown, fragments A/B, A, or B was inserted
into the CD4 promoter-driven pGL3 reporter, and then cotransfected into the CD4CD8 thymoma cell line AKR1G1 with a control reporter
pRL-TK. The bar graph represents the mean luciferase activity generated from the construct on the left; error bars represent one standard
deviation. Induction is normalized against the promoter only construct.
(C) The ISOT intronic B fragment drives CD4 transgene expression in DP thymocytes. FACS analysis of transgene marker expression in DN,
DP CD4 SP, and CD8 SP thymocytes. Thymocyte subpopulations were electronically gated as previously described, and marker expression
was assessed (Duncan et al., 1996). The pM and pN transgene constructs are identical except that pM also contains the 1 kb B fragment as
defined transient transfection reporter assay. pN transgene expression displayed some PEV. Marker staining: gray-filled polygon, transgenic
thymocytes; black line, nontransgenic littermate.
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confirm that the 1 kb B fragment contains a traditionally known to contain the HSC, implying that the CD4 locus
enhancers function very early in hematopoiesis.defined transcriptional enhancer.
To confirm that the 1 kb B fragment functions as an
enhancer in vivo, this fragment was tested by transgenic The Thymocyte Enhancer Is Active at Low Levels
reporter assay (Figure 3C). The pM construct contains in Most Hematopoietic Lineages
the minimal promoter and PE, silencer, and the 1 kb B Previous analyses of mice transgenic with constructs
fragment as defined by transient transfection. The pN containing the promoter, PE, and TE indicated that these
construct is the same as pM except that it does not enhancers function in most hematopoietic lineages (Ad-
contain this 1 kb TE. As shown in Figure 3C, marker lam et al., 1997). Similar analyses of mice transgenic with
expression in pM transgenic mice was detected in DP pI construct, which contains the same control elements,
and CD4 SP but not DN or CD8 SP thymocytes. In con- yielded comparable results. However, marker expres-
trast, marker expression was only detected on a subset sion was lower in these other hematopoietic lineages in
of CD4 SP thymocytes from pN transgenic mice. These the pI transgenic mice in comparison to our previous
data indicate that the pM construct contains all the nec- analyses of the B transgenic mice. There are two possi-
essary cis-acting elements for expression of CD4 includ- bilities for these minor differences. When generating
ing an enhancer capable of activating transcription in the pI construct we may have inadvertently deleted an
DP thymocytes. undefined upstream positive regulatory region that can
activate CD4 transcription in these other hematopoietic
populations. However, we believe that these expressionCD4 Regulation in DN Thymocytes
differences are due to changes in the detection method;We wished to correlate thymocyte development with
previous studies had used two-step anti-marker anti-CD4 control element function. Therefore, we compared
body staining, whereas studies presented herein havethe functional specificities of transgenes that contained
used directly conjugated anti-marker antibody. Theseboth the PE and TE (the pI construct; Figure 3C) to those
data may represent transgene expression levels moreof transgenes that contained the PE, TE, and the CD4
accurately (Figure 4B) (Adlam et al., 1997). In contrast tosilencer (the pM construct, Figure 3C; the cosC construct,
the marker expression observed in CD4 hematopoieticdata not shown). The pI transgenic mice expressed the
populations in the B and pI transgenes, we could notmarker in most DN cells. In contrast, pM and cosC trans-
detect marker expression in any CD4 population iso-genic thymocytes (Figure 3C and data not shown) do not
lated from mice transgenic with the silencer-containingexpress the marker in either DN or CD8 SP thymocytes.
cosC and pM constructs (Figure 4C and data not shown)These data indicate that although the TE is active in DN
(Adlam et al., 1997). These data indicate that althoughT cells, the silencer is also active, capable of overriding
the TE is active in most lymphoid lineages, the CD4TE activity and repressing CD4 transcription.
silencer is also active and represses CD4 transcription.Interestingly, mice transgenic with constructs that
contain the TE without the silencer (the pI, pP, and pQ
transgenic mice; Figure 3C and data not shown) express Developmental Changes in Silencer Function
Mediate CD4 Expression in Transitional-Stagethe marker in a trimodal manner within the DN popula-
tion, suggesting that TE function changes during DN DP Thymocytes
CD4 expression fluctuates throughout the transitionthymocyte development. To determine the DN sub-
classes in which the TE functions, we analyzed the trans- process from DP to mature SP stages. At least part of
this modulation is the result of transcriptional controlgenic marker expression in DN subpopulations isolated
from pI transgenic mice (Figure 4A). We detect variable mechanisms (Siu et al., 1994; Takahama and Singer,
1992). Although the final downregulation of CD4 as thebut consistently very low levels of marker expression
on the DN1 population. However, upon T cell commit- CD8 SP T cell develops requires the full induction of the
CD4 silencer, how CD4 expression is modulated at thement at the DN2 stage, marker expression increased
330-fold. Marker expression subsequently decreases as intervening transitional stages is unclear. The partial
downregulation of CD4 in CD4loCD8lo thymocytes couldthe DN progresses through the DN3 and DN4 stages
(Figure 4A). Thus, TE function directly correlates to spe- be the result of partial silencer function or a switch in
enhancer usage. In this second “enhancer switch”cific stages in early T cell lineage commitment, sug-
gesting that this element is responsive to the signals model, the CD4loCD8lo thymocyte represents a transi-
tional stage in which the TE has stopped functioningthat mediate these processes (Kondo et al., 1997; Mac-
Donald et al., 2001; Zuniga-Pflucker et al., 1995). but the PE has not yet become fully functional.
To distinguish between these possibilities, we ana-Recent studies had indicated that many lineage-spe-
cific genes are transcribed prior to lineage commitment lyzed pI, B, cosC, and pM transgenic thymocytes to
determine marker expression in each thymocyte transi-(Hu et al., 1997; Miyamoto et al., 2002). Furthermore,
Igarashi et al. have recently identified a marrow-derived tional stage. Thymocytes were gated into the different
transitional subpopulations on the basis CD4, CD8, andlymphoid-restricted linc-kithi RAG1 transcribing popu-
lation that also express CD4. These data predict that CD3 or CD69 expression (Lucas and Germain, 1996;
Suzuki et al., 1995) and each analyzed for marker expres-the CD4 locus enhancers may be active prior to the CLP
seeding the thymus. To test whether the CD4 locus sion (Figure 4B). If the changes in CD4 expression in
these transitional populations were due to silencer func-enhancers are indeed active, we analyzed the expres-
sion of the pI transgene in the linc-kitSca-1 popula- tion, we predict that mice transgenic with constructs
that contain the silencer would express the marker genetion of the bone marrow (Figure 4A). We could detect
pI expression in the linc-kitSca-1 population that is in a similar manner as endogenous CD4. In contrast,
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Figure 4. Mapping of CD4 cis-Element Interactions throughout Thymocyte Development
Marker staining: gray filled polygon, transgenic thymocytes; black line, nontransgenic littermate.
(A) The thymocyte enhancer is most active at T cell lineage commitment. Marrow-derived HSCs and thymic DN subpopulations were electroni-
cally gated as described in the Experimental Procedures, and marker expression was assessed on each population.
(B) The thymocyte enhancer can activate low-level transcription in many hematopoietic lineages. The pI transgene expression was assessed
using marrow-derived pre/proB cells and erythroblasts and splenic macrophages, granulocytes, and B cells. Populations were identified as
previously described (Adlam et al., 1997). Marker expression was not detected in populations from transgenes either containing the silencer
and both enhancers or containing the PE but lacking the TE and silencer (data not shown).
(C) The CD4 silencer is the dominant cis-element and is partially activated in response to positive selection. Transgenic DP and transitional
populations were electronically gated on the basis of CD4, CD8, and CD3 expression (Lucas and Germain, 1996), and then transgene marker
expression level was assessed as indicated.
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Figure 5. The Thymocyte Enhancer Is De-
pendent on Nontraditional Interactions with
the Proximal Enhancer
Four-color FACS analysis of transgene
marker expression in DN, DP CD4SP, and
CD8SP thymocytes. Thymocyte subpopula-
tions were electronically gated as previously
described, and marker expression was as-
sessed (Duncan et al., 1996).
marker expression in the transitional populations in mice TE only express marker in mature T cells (Figures 2, 3,
and 4). In total, 15 pK, 11 pL, and 3 pS transgenic mousetransgenic with constructs that contain only the two
enhancers would not change. Alternatively, if the modu- lines were generated (Figure 5). Surprisingly, marker ex-
pression was not detectable on any cell population inlations of CD4 expression are due to a switch in en-
hancer usage, the expression of all four transgenes any of these 29 different transgenic mouse lines. Thus,
both the TE and the PE are required for CD4 expressionshould decrease, irrespective of the presence of the
silencer. in immature thymocytes, indicating that the TE must
interact with the PE to drive CD4 expression duringAs shown in Figure 4C, mice transgenic with con-
structs that do not contain the silencer (B and pI) main- thymocyte development. These data support a model
in which CD4 expression early in thymopoiesis is medi-tain high levels of marker expression in all subpopula-
tions, including the transitional CD4loCD8lo and CD4CD8lo ated by a hierarchical series of interactions among the
CD4 transcriptional control elements.populations. In contrast, marker expression from the
silencer-containing cosC and pM constructs is re-
pressed in the CD4loCD8lo population relative to DP and A CD4 Locus Control Region
CD4CD8lo populations. Marker expression remains Locus control regions contain a tissue- or stage-specific
high in CD4 SP thymocytes but is completely extin- enhancer and a region that protects against position
guished in the CD4loCD8 and CD8SP populations (Fig- effect variegation. In transgenic reporter assays, LCRs
ure 4C and data not shown) (Siu, 2002). These data convey position-independent expression of a linked re-
indicate that the CD4 silencer partially is induced to porter transgene in a copy number-dependent manner
function in response to positive selection, thus leading (Festenstein and Kioussis, 2000). Previous data indi-
to a decrease in CD4 expression in the CD4lo thymocyte cated that both B and cosC transgenic constructs may
populations. contain an LCR. All mice transgenic with these two con-
structs expressed the marker gene in a tissue-specific,
PEV-resistant, and copy number-dependent mannerThymocyte Enhancer Activity Is Dependent
on the Proximal Enhancer (Siu et al., 1994). In contrast, only half of the mice trans-
genic with the pA5UA construct express the marker,To dissect the contributing roles of the TE and PE during
T cell development, we generated mice transgenic with often in a variegated manner. Furthermore, there was
no linear correlation of transgene copy number toconstructs that contained the TE and CD4 promoter but
lacked the PE (pK, pL, and pS). We then compared the marker gene expression. Such variegation could not be
attributed to the silencer, as it was observed at the samespecificity of marker expression in mice transgenic with
these constructs to that of mice transgenic with con- frequency irrespective of the presence or absence of
this element (Figure 1) (Adlam et al., 1997; Duncan etstructs that contained the PE alone (pN and pTG; Figure
3C) (Adlam et al., 1997) or both the PE and TE (pI, pM, al., 1996). Taken together, these data suggested that
the cosC and B constructs contained an LCR, whereaspP, pQ, B, and cosC; Figures 3C and 5 and data not
shown) (Adlam et al., 1997). As described above, mice pA5UA did not.
To identify the LCR element, we focused on studyingtransgenic with constructs containing both the TE and
PE express marker in DP thymocytes and mature T cells, DH11-17, which encompass those DH sites present on
the cosC and B constructs but not on the pA5UA con-whereas mice transgenic with constructs that lack the
CD4 Gene Regulation throughout Thymopoiesis
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struct (Figure 1). Therefore, we evaluated the ability of Discussion
transgene reporters containing different combinations
Functional Specificity of the Thymocyte Enhancerof these DH sites to overcome position-dependent ex-
Data from three different groups have suggested thatpression (Figure 1) or variegation (data not shown). Both
a second enhancer is required for CD4 expression inthe pH and pM constructs lack the 3 kb DH17; only
immature thymocytes (Adlam et al., 1997; Boyer et al.,half of the transgenic mouse lines with these constructs
1997; Salmon et al., 1996; Uematsu et al., 1997). In thisexpress the marker and often do so in a variegated
study, we identify this enhancer as a part of a novel CD4manner (Figure 1 and data not shown). In contrast, the pI
LCR. The requirement of this enhancer element for DPconstruct contains the entire 3 kb DH17; all pI transgenic
thymocytes conflicts with a single report that suggestedmice expressed the marker without variegation (Figures
that the PE was capable of inducing robust expression1 and 6A, and data not shown). These data suggest that
in all thymocytes (Sawada et al., 1994). The reasonsthere is a region located in the 5 2 kb XhoI/BamHI A
for this discrepancy are unclear. It is possible that anfragment of DH17 that conveys position-independent
endogenous enhancer present at the position of trans-transgene expression and that this region is distinct
gene insertion in the reported founder inadvertently al-from the 1 kb TE, as defined by PM.
tered marker gene expression. Similar position effectsTo identify the region contained within the 2 kb XhoI/
have been reported previously; the CD8 SP-specificBamHI A fragment that conveyed true position-indepen-
minigene constructs were expressed in CD4 SP T cellsdent expression, we generated additional transgenic
in two of eight founder lines, and the authors concluded
mice. We then correlated the site of transgene integra-
that the low level of expression seen in these mice was
tion, transgene copy number, marker expression level,
not physiologically significant (Hostert et al., 1997b).
and variegation to each of these transgene constructs. Alternatively, differences between minigene constructs
The pP transgene contains the PE, CD4 promoter, and used in different studies may have led to aberrant trans-
the 3 kb fragment of DH17 used to generate pI. The pQ gene marker expression. To control for such effects, we
transgene contains the minimal PE, CD4 promoter, and have generated 166 expressing transgenic lines using 41
a 1.9 kb 3 fragment of DH17 that includes the TE, de- different CD4 control element constructs. Forty different
rived only from the first intron of ISOT. The pR transgene expressing founder lines generated from seven different
is pH with the minimal 1 kb TE added; it is therefore transgenic constructs that contain the TE express the
similar to pI except that the 5 2 kb A fragment of DH17 marker in immature thymocytes, whereas 124 express-
has been deleted (Figure 6A). As shown in Figure 6A, ing transgenic founder lines using 34 different con-
we detect robust nonvariegating marker expression on structs lacking the TE do not (Adlam et al., 1997; Allen
the surface of pI, pP, and pQ transgenic thymocytes, and et al., 1999; Duncan et al., 1996; Siu et al., 1994). Only
this expression is independent of the site of transgene twice have we detected marker expression in immature
integration, including integration directly into centro- DP thymocytes from transgenes that do not contain
meric or telomeric DNA. In contrast, the pR transgene the TE; data from these two lines were not included.
that lacks the 2 kb A fragment displays classical integra- Although there has been a report that the 3 end of the
tion site-dependent position effects, such as marker first intron of human CD4 may contain a thymocyte-
specific promoter, previous studies had failed to identifyexpression variegation and in one case complete trans-
such a promoter in the mouse locus (Hanna et al., 1994).gene silencing. Taken together, these data indicate that
Taken together, these data support the hypothesis thatthe 5 0.9 kb fragment of ISOT intron 1 contains a region
a separate enhancer is required for proper CD4 genethat conveys position-independent expression from the
expression throughout thymopoiesis (Adlam et al.,linked reporter. Deletion of this region, as defined with
1997).the pR transgene, illustrates that the TE function is dis-
As shown in Figure 1, the TE maps to the first intronsectible from the element that protects against PEV.
of the ISOT gene; it is thus unclear how the CD4 silencerTo test if this intronic region of ISOT conveyed copy
represses TE function in DN cells without affecting ISOTnumber-dependent expression, we compared the
gene expression as well. ISOT is widely expressed inmarker expression levels on CD4CD3 splenocytes to
most cells including both DN and DP cell lines, indicatingtransgene copy number as assessed by Southern blot
that the silencer does not repress ISOT expression inand phosphoimaging. As shown in the upper scatter
situ (Ansari-Lari et al., 1996) (data not shown). The pres-
plot of Figure 6B, there is a direct linear relationship
ence of a control element critical for the expression of
between transgene copy number and marker expression a tissue-specific gene within the locus of a ubiquitously
with constructs that contain the 3 kb DH17 (pI and pP) expressed gene is not unprecedented. The -globin en-
or the 1.9 kb ISOT intronic fragment (pQ). In contrast, as hancer is present within the intron of another ubiqui-
shown in the lower scatter plot of Figure 6A, transgene tously expressed housekeeping gene. Interestingly, the
constructs that lack this region (pH, pM, p,N and pR) -globin enhancer is repressed in all nonreticulocyte
do not express the transgene reporter in a copy number- cells, whereas the housekeeping gene is expressed in all
dependent manner; there is no linear relationship be- cells (Vyas et al., 1992). Other promoters and enhancers
tween transgene copy number and marker expression. have inherent properties that only allow their specific
These data indicate that the 0.9 kb intronic fragment of functional interaction. For example, the enhancers for
ISOT, located immediately upstream of the TE, conveys the Drosophila melanogaster gene decapentaplegic
copy number-dependent transgene expression. To- (dpp) are actually located closer to the promoters of
gether these data satisfy the criteria that the 1.9 kb the SLY1 homologous (Slh) and out-at-first (oaf) genes;
nonetheless, the dpp enhancers can only induce tran-intronic fragment of ISOT is a classical LCR.
Immunity
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Figure 6. The CD4 Control Elements Utilize a Locus Control Region
(A) The CD4 locus control region conveys position-independent expression of the linked marker. The centromeres and the site of transgene
integration were revealed by in situ fluorescence hybridization of metaphase chromosomes from the spleens of pI, pP, pQ, and pR transgenic
mice and correlated with marker expression in peripheral CD4CD3 T cells. A, XhoI/BamHI fragment of DH17; B, BamHI/EcoRV fragment of
DH17. FACS plots shown are representative of the marker expression from the transgenic line shown in the adjacent FISH panels. The upper
left FISH panel shows transgene staining (green), the upper right panel shows centromeric staining (red), and the lower panel is the three-
color integrant of centromeric and transgene staining. Chromosomal DNA was revealed with DAPI.
(B) The CD4 locus control region conveys transgene copy number-dependent expression of the linked marker. Transgene copy number was
CD4 Gene Regulation throughout Thymopoiesis
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Figure 7. A Model of CD4 Transcriptional
Regulation throughout Thymocyte Devel-
opment
The TE and PE are active in DN thymocytes,
but the CD4 silencer actively represses tran-
scription. These DN thymocytes differentiate
to become DP thymocytes, at which point the
silencer becomes inactive, allowing the TE and
PE to activate CD4 expression. At both DN and
DP stages, the PE alone is not sufficient to
drive CD4 expression. At positive selection,
the silencer becomes partially active, repress-
ing CD4 transcription in the CD4loCD8loCD3lo
transitional population. The silencer then
ceases to act in the CD4CD8loCD3hi transi-
tional population. Hereafter, the pathways of
CD4 SP and CD8 SP T cells diverge. If the
CD4CD8loCD3hi cells thymocyte is fated to
become a CD4 SP T helper cell, CD8 expres-
sion is extinguished, and the thymocyte en-
hancer is no longer required; the proximal
enhancer alone can drive CD4 expression. If
the CD4CD8loCD3hi cells thymocyte is fated
to become a CD8 SP T cytotoxic cell, the
silencer extinguishes CD4 expression.
scription from the dpp promoter (Merli et al., 1996). Thus, to activate CD8 expression in immature DP thymocytes
(Ellmeier et al., 1999; Hostert et al., 1998). Thus, bothspecificity of dpp enhancer function is the result of pro-
moter specificity and not domain boundaries. Our data CD4 and CD8 genes appear to be controlled by elements
that function at different stages of development.indicate that the TE function is dependent on the pres-
ence of the PE. We propose that the TE does not resem- Thymocyte enhancer activity in many hematopoietic
lineages and the HSC is not surprising given the endoge-ble a traditional enhancer in that it does not function
directly on its cognate promoter. Instead, the TE exerts nous CD4 gene expression observed by others in these
populations (Frederickson and Basch, 1989; Igarashi etits effects indirectly by altering the function of the PE,
which in turn enhances the CD4 promoter (Figures 5 al., 2002; Wineman et al., 1992; Wu et al., 1991). It has
been demonstrated that many lineage-specific genesand 7). Thus, to repress CD4 transcription in DN thymo-
cytes, the silencer need only block the interactions of are promiscuously expressed in progenitor cell popula-
tions prior to lineage commitment. The significance ofthe PE with the promoter and not TE function directly.
In this model, the silencer need not act over great dis- this “promiscuous” gene expression in these progenitor
cells is not known. Surprisingly, we do not observetances or interact directly with the TE, and therefore
would not risk silencing the transcription of intervening marker expression from transgenes that contain both
enhancers and the silencer in these populations, indicat-genes in vivo.
Our data indicate that the induction of TE function ing the silencer is the dominant control element. We
hypothesize that the silencer may have a stronger re-serves as a marker of T cell commitment. Preliminary
transient transfection data indicate that the TE function pressive effect in a transgenic context than in the endog-
enous CD4 locus.does not function in CD4 SP T cells, suggesting that
cessation of TE function may also serve as a marker for
final thymocyte development (data not shown). Analo- The Thymocyte Enhancer Is Part of a CD4 Locus
Control Regiongous stage-specific enhancer activities have been re-
ported in the CD8 locus. The CD8 gene locus contains The data presented here clearly indicate that the control
of CD4 expression in immature thymocytes is quite dif-two genes encoding CD8 and CD8 separated by three
clusters of DH sites. By transgenic reporter assay, the ferent from that of mature T cells. We propose that the
CD4 LCR acts to maintain an open chromatin structureCD8 DH cluster II (CII) was incapable of driving expres-
sion in any thymocyte population (Hostert et al., 1997a). around the complete locus, thus ensuring that CD4 is
expressed in immature thymocytes until the cessationDH cluster III (CIII) was capable of driving expression,
but only in mature postselection T cells, analogous to of positive selection, when the transcriptional state of
CD4 becomes immutable. Similarily, in situ mutagenesisthe CD4 PE. Addition of CII allowed expression in both
DP and SP thymocytes; thus, CII must interact with CIII studies of the CD8 locus have indicated that CD8 gene
assessed by Southern blotting tail DNA as outlined in the Experimental Procedures. Transgene expression level was assessed as mean
fluorescence intensity of anti-HLA-B7 staining on splenic CD4 T cells. The top scatter plot illustrates the correlation of marker expression
and copy number of transgenic CD4 T cells generated from constructs that contain the CD4 LCR. The bottom scatter plot illustrates the
correlation of marker expression and copy number of transgenic CD4 T cells generated from constructs that do not contain the CD4 LCR.
Note that many lines display variegated marker expression including complete transgene silencing; the mean fluorescence intensity is inclusive
of all CD4CD3 splenic T cells assayed.
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regulation is quite different before and after final thymo- silencer can only function over relatively short distances
and thus exerts its effects only on the PE and the CD4cyte maturation. Indeed, in one report, multiple clusters
had to be deleted in order to effect CD8 transcription promoter. The other genes in the CD4 locus are shielded
from the silencer primarily by distance. How is TE func-in DP thymocytes. Surprisingly, CD8 expression was
also variegated in these thymocytes. Analogous experi- tion in the DN thymocyte then repressed? Our data indi-
cate that the TE cannot function on the CD4 promoterments involving the deletion of one of these clusters
also led to variegated CD8 expression in DP thymocytes. directly but requires the presence of the PE to function.
Although the hierarchy model predicts that the largeTherefore, it was hypothesized that these enhancers
increase the probability of expression, but once expres- intervening distance inhibits the silencer from repress-
ing TE function, the silencer need only block PE functionsion is established they are no longer required (Ellmeier
et al., 2002; Garefalaki et al., 2002). We propose that the to repress CD4 expression at the DN stage. By blocking
only PE function, the silencer can inhibit the functionCD4 LCR has a similar function for the CD4 locus; that
is, by maintaining an open chromatin structure the CD4 of the TE indirectly without affecting the expression of
genes adjacent to the TE in the genome (Figure 7).LCR increases the probability of transcription of the CD4
gene. Interestingly, the presence of the CD4 LCR in the Our data indicate the regulation of the CD4 control
elements is linked to the signals that direct the thymo-midst of the gene-rich cluster implies that it may function
as a LCR for all of the genes in this locus and not just cyte through the thymocyte transitional stages. Onset
of TE function in the DN population directly correlatesthe CD4 gene. Previous data from our group indicated
that TE and PE function are restricted the hematopoietic with T cell commitment, indicating that the factors that
mediate TE function may be induced by the same mech-lineages, as B transgene expression was not detected
in nonhematopoietic cells (Adlam et al., 1997). However, anisms that mediate this commitment. Thus, the TE pro-
vides an ideal molecular target to study the signals thatadditional experiments are necessary before definitive
conclusions can be drawn about LCR function. drive T cell developmental through these transitions.
Control of CD4 Expression during Thymopoiesis Experimental Procedures
The data presented here allow us to draw a model of
CD4 gene regulation during thymopoiesis (Figure 7). Transgenic Constructs and Mice
The generation of cosC, B, pA5UA, and pTG have been describedCommon lymphoid progenitors enter the thymus and
(Adlam et al., 1997; Duncan et al., 1996; Siu et al., 1994). The pHacquire low levels of CD4 on the cell surface (Michie et
transgene was generated by ligation of a 6 kb fragment isolated byal., 1998). As the thymocyte proceeds through the DN
partial BamHI digestion from cosmid J31 into the EcoRV site of
stages, all four of the CD4 control elements are active; pTG. To generate the pI transgene, the 6 kb BamH1 fragment was
since the silencer is dominant, CD4 expression is extin- blunt ligated into pKS to which the Sac1 site was adapted to an
Asc1 site. The Sac1 site of pTG was changed to an Asc1 site, andguished. As the DN cells successfully advance to the DP
the transgene was excised with Cla1 and Asc1 and ligated into thestage, silencer function ceases, allowing the thymocyte
Cla1 and Asc1 sites of pKS11-16, generating pTG11-16. Hereafter,enhancer to activate transcription via interactions with
the 3 kb Xho1/EcoRV fragment of cosmid clone 4J2 was ligated intothe PE. The initiation of positive selection induces partial
the Not1 site of pTG11-16. Orientation was confirmed by restriction
silencer function, causing a transient downregulation of digestion. Both pH and pI transgenes were excised with Asc1 and
CD4 expression in the CD4loCD8lo population, where it Sac1. The pK transgene was generated by ligating a pfu/taq-gener-
ated TE (5-GGATCCGCCCCCTTCATCACCC and 5-GCGGCCGCGis believed that the T cell selection and lineage commit-
GCAACACTTGCTGAGAGAGCCAGACA) into pCR2.1 (Invitrogen)ment processes begin to occur (Corbella et al., 1994;
and sequenced. The insert was released with Not1 digestion andLucas and Germain, 1996; Singer, 2002). Upon the ces-
then ligated into the Not1 site of pwpB7. The pL transgene wassation of positive selection, the PE obtains the ability
generated by ligation of the 484 bp CD4 silencer into the EcoRV
to induce CD4 expression on its own (Adlam et al., 1997; site of pK. To generate the pN transgene, the PE was PCR ampliflied
Duncan et al., 1996). Concurrent with positive selection, (5-ACCAATCTACCTCCACCCTG and 5-TGTTGGCGTTCAAATT), li-
gated into pCR2.1, and sequenced. The PE was then ligated intoDP thymocytes commit to either a CD4 SP or CD8 SP
the Not1 site of pwpB7. The silencer was then ligated in to thecell fate, downregulating either CD8 or CD4 respectively
EcoRV site. The pM transgene was generated by PCR of the TE(Fowlkes and Pardoll, 1989). CD4 repression in CD8 SP
using pfu/taq and subcloned into pCR2.1topo and sequenced. Theis mediated by action of the CD4 silencer (Sawada et
PE was then ligated into the EcoRV. Both enhancers were then
al., 1994; Siu et al., 1994). Alternately, if fated to a CD8 SP released together by digestion with Not1 and ligated to Not1-
lineage, CD4 expression is extinguished by full activity digested pwpB7. The pR transgene was generated by ligation of the
3 kb Xho1/EcoRV from cosmid clone 4J1 into the Not1 site of pwpB7of the silencer (Sawada et al., 1994; Siu et al., 1994).
(Siu et al., 1994). To generate the pP and pQ transgenes, pfu poly-Therefore, CD4 gene expression during thymopoiesis is
merase generated PCR products subcloned into pCR2.1. Primersregulated by a hierarchical series of element interac-
used to generate amplicons: 5-GAGCTCCCACTTGCTTGTTGCGTtions. Interestingly, these data indicate that silencer
GGCAGAGGCC, 5-CAGAACAATCTGGCAACACTTGCTGAG, 5-GAG
function correlates only to CD4 expression and not to CTCACACGCCGGTAAGCCCATTCCCCACGC. The PE was then in-
fate lineage commitment. Future studies of silencer serted into the EcoRV site. Both enhancers were excised with Sac1/
Not1 and ligated into Sac1/Not1-digested pwpB7. The pR transgenebinding factors must take into account that these factors
was generated by insertion of a Not1 fragment containing the 1 kbmay be responding either to signals that mediate lineage
TE into the Not1 site of pH. The pS construct was generated bycommitment or to signals that mediate the commitment-
inserting the reverse orientation 3 kb CD4 LCR into the Not1 site ofindependent modulations of CD4 and CD8 in the DP
pwpB7. The pN, pM, pK, pL, pP, pQ, pR, and pS transgenes were
thymocyte. excised with Sac1 and Cla1. DNA and was prepared and injected
The CD4 element hierarchy model provides a mecha- into mouse pronuclei as previously described (Duncan et al., 1996).
Transgenesis was identified by Southern hybridization, using the 1nism for specificity of TE function. In this model, the CD4
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